Research Topics
| R N ColerSummaryAffiliation: Infectious Disease Research Institute Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Development of a leishmaniasis vaccine: the importance of MPLSteven G Reed
Corixa Corporation, Seattle, WA, USA
Expert Rev Vaccines 2:239-52. 2003..This vaccine has potential application in both the prevention and treatment of leishmaniasis...- Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosisR N Coler
The Infectious Disease Research Institute, Seattle, WA 98104, USA
J Immunol 166:6227-35. 2001..tuberculosis. Thus, these results suggest that Mtb 8.4 is a potential candidate for inclusion in a subunit vaccine against TB... 
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasisRhea N Coler
Infectious Disease Research Institute, Seattle, Washington 98104, USA
Infect Immun 70:4215-25. 2002....- Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human diseaseA Campos-Neto
Infectious Disease Research Institute, Seattle, Washington 98104, USA
Infect Immun 69:4103-8. 2001..The remarkable protection induced by LmSTI1 and TSA in an animal model that is evolutionarily close to humans qualifies this antigen combination as a promising candidate subunit vaccine against human leishmaniasis... - Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c miceA Campos-Neto
Infectious Disease Research Institute Corixa Corporation, Seattle, Washington 98104, USA
Infect Immun 70:2828-36. 2002.... - Evaluation of DPPD, a single recombinant Mycobacterium tuberculosis protein as an alternative antigen for the Mantoux testA Campos-Neto
Infectious Disease Research Institute, Seattle, WA 98104, USA
Tuberculosis (Edinb) 81:353-8. 2001..Because the DPPD gene is not present in non-tuberculous bacilli, these results suggest that this molecule can be an additional tool for a more specific diagnosis of tuberculosis... 
Adjuvants for malaria vaccinesR N Coler
Infectious Disease Research Institute, Seattle, WA 98104, USA
Parasite Immunol 31:520-8. 2009..In this minireview, we outline the current state of adjuvant research and development as it pertains to effective malaria vaccines...- Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvantYasir A W Skeiky
Corixa Corporation, 1124 Columbia Street, Suite 200, Seattle, WA 98104, USA
Vaccine 20:3292-303. 2002.... - Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantYasuyuki Goto
Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
Vaccine 25:7450-8. 2007..The results indicate that SMT/MPL-SE can be an effective vaccine candidate for use against VL... - Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsRhea N Coler
Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
Infect Immun 75:4648-54. 2007..The Leish-111f+MPL-SE product we report here is the first defined vaccine for leishmaniasis in human clinical trials and has completed phase 1 and 2 safety and immunogenicity testing in normal, healthy human subjects... - Second-generation vaccines against leishmaniasisRhea N Coler
The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA
Trends Parasitol 21:244-9. 2005..In addition, several antigens have been identified and characterized that might be potential vaccine candidates. In this article, we focus on advances made with second-generation vaccines against leishmaniasis... - Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infectionElizabeth G Rhee
Cellular Immunology Section, Vaccine Research Center, Bethesda, MD 20892, USA
J Exp Med 195:1565-73. 2002.... - Taking toll: lipid A mimetics as adjuvants and immunomodulatorsDavid H Persing
Corixa, Suite 200, 1124 Columbia Street, Seattle, WA 98104, USA
Trends Microbiol 10:S32-7. 2002..Novel approaches to vaccine development could benefit from taking full advantage of the effects of these compounds on innate and adaptive responses... - Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteinsYasuyuki Goto
Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
Infect Immun 74:3939-45. 2006..Our results suggest that TR regions from the novel L. infantum proteins identified in this study are immunodominant B-cell epitopes and may represent good candidates for serodiagnosis of VL... - Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complexYasuyuki Goto
Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
Infect Immun 75:846-51. 2007..0070, LinJ25.1100, LinJ27.0400, and LinJ29.0110, which were from the 42 uncharacterized proteins, are also antigenic. The results suggest the validity of this approach for identifying leishmanial antigens of serological significance... - Immunotherapy for drug-refractory mucosal leishmaniasisRoberto Badaro
Federal University of Bahia, Salvador, Brazil
J Infect Dis 194:1151-9. 2006..CONCLUSIONS: These data support the concept that vaccine therapy with a defined antigen combination, used with standard chemotherapy, is a safe and effective approach to treat drug-refractory ML...
Research Grants
- Characterization of a vaccine against Chlamydia trachomatisRHEA COLER; Fiscal Year: 2007....